Long-term intellectual and behavioral outcomes of children with febrile convulsions.

Department of Paediatrics, Addenbrooke's Hospital, Cambridge, United Kingdom.
New England Journal of Medicine (Impact Factor: 54.42). 07/1998; 338(24):1723-8. DOI: 10.1056/NEJM199806113382403
Source: PubMed

ABSTRACT Hospital-based studies have reported that children with febrile convulsions have subsequent mental retardation and behavior problems. In contrast, population-based studies have reported a better outcome.
We identified 398 children with febrile convulsions among 14,676 children enrolled in the Child Health and Education Study, a national population-based study in the United Kingdom of children born in one week in April 1970. The children were comprehensively assessed at the age of 10. After excluding 16 children who had neurodevelopmental problems before their first febrile convulsion and 1 child whose case was atypical, we studied 381 children, 287 with simple febrile convulsions and 94 with complex febrile convulsions. We compared them with the rest of the cohort using measures of academic progress, intelligence, and behavior that included questionnaires, standardized tests, and formal tests.
At the 10-year assessment, only 4 of 102 measures of academic progress, intelligence, and behavior differed significantly between the entire group of children with febrile convulsions and the group without febrile convulsions -- no more than would be expected by chance. Similar results were found when children with simple febrile convulsions and those with complex febrile convulsions were analyzed separately. The children with recurrent episodes of febrile convulsions had outcomes similar to those of the children with only one episode each. Special schooling was required for more children who had febrile convulsions in the first year of life than for those who had had them later in life (5 of 67, or 7.5 percent, vs. 4 of 265, or 1.5 percent; P=0.02), but these numbers were small.
Children who had febrile convulsions performed as well as other children in terms of their academic progress, intellect, and behavior at 10 years of age.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. The study aimed to evaluate the influences of coadministration of antiepileptic drugs (AEDs) on an antimalarial candidate 99/411 pharmacokinetic (PK) profile. Method. For this, single oral dose PK drug interaction studies were conducted between 99/411 and FDA approved AEDs, namely, Phenytoin (PHT), Carbamazepine (CBZ), and Gabapentin (GB) in both male and female SD rats, to assess the coadministered and intersexual influences on 99/411 PK profile. Results. Studies revealed that there were no significant alterations in the PK profile of 99/411 upon PHT and CBZ coadministration in both male and female rats, while systemic exposure of 99/411 was significantly increased by about 80% in female rats upon GB coadministration. In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL. Overall, it was concluded that simultaneous administration of AEDs with 99/411 excludes the requirements for dose adjustment, additional therapeutic monitoring, contraindication to concomitant use, and/or other measures to mitigate risk, except for GB coadministration in females. These findings are further helpful to predict such interactions in humans, when potentially applied through proper allometric scaling to extrapolate the data.
    Malaria research and treatment. 01/2014; 2014:756965.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was performed to compare the clinical features between febrile convulsions and benign convulsions associated with viral gastroenteritis. We retrospectively reviewed the medical records of 706 children admitted to the Sunlin Hospital for either febrile convulsions or benign convulsions with viral gastroenteritis, between January 1, 2006, and December 31, 2009. We classified them into group A for febrile convulsions (N = 631), group B for non-rotavirus gastroenteritis (N = 43) and group C for rotavirus gastroenteritis (N = 32). Then we analyzed and compared the characteristics between the three groups. The mean ages (± SD) of group A, B and C were 28.3 ± 17.9, 21.2 ± 22.0, and 22.0 ± 18.7 months, respectively. Group A admissions were prevalent in the spring, and group C admissions were prevalent in the winter. There was a family history of febrile convulsions in 55.6% of group A patients, 46.5% of group B patients, and 34.4% of group C patients. Cluster convulsions during hospitalization were observed more in group B and group C than in group A (23.3%, and 18.8% vs. 6.3%, p < 0.01). In afebrile convulsions with diarrhea, recurrence occurred in 33.3% of patients, while recurrence occurred in only 10.3% in febrile cases (p = 0.015). All studied groups showed favorable prognoses. However, the groups differed in the following characteristics: distribution of the month of admission, age, the family history of febrile convulsions, fever occurrence, and recurrence. In afebrile convulsions with gastroenteritis, cluster convulsions were more likely to occur within 24 h from admission.
    Journal of epilepsy research. 03/2011; 1(1):19-26.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Temporal lobe epilepsy (TLE) and hippocampal sclerosis (HS) commonly arise following early-life long seizures, and especially febrile status epilepticus (FSE). However, there are major gaps in our knowledge regarding the causal relationships of FSE, TLE, HS and cognitive disturbances that hamper diagnosis, biomarker development and prevention. The critical questions include: What is the true probability of developing TLE after FSE? Are there predictive markers for those at risk? A fundamental question is whether FSE is simply a marker of individuals who are destined to develop TLE, or if FSE contributes to the risk of developing TLE. If FSE does contribute to epileptogenesis, then does this happen only in the setting of a predisposed brain? These questions are addressed within this review, using information gleaned over the past two decades from clinical studies as well as animal models.
    Journal of the American Society for Experimental NeuroTherapeutics 03/2014; · 5.38 Impact Factor